文献速递眼底病与葡萄膜炎

利妥昔单抗治疗对传统免疫抑制治疗难治性非感染性后葡萄膜炎患者的长期结局

LONG-TERM OUTCOMES OF RITUXIMAB THERAPY IN PATIENTS WITH NONINFECTIOUS POSTERIOR UVEITIS REFRACTORY TO CONVENTIONAL IMMUNOSUPPRESSIVE THERAPY.
PubMed 文献 · Retina · 2018-01-01

回顾性病例系列纳入2010至2015年接受静脉利妥昔单抗治疗的11例(21眼)难治性非感染性后葡萄膜炎患者,平均随访29.3±7.8个月;末次随访时9例(81.8%)患者荧光素眼底血管造影炎症体征得到控制,最佳矫正视力从基线20/80(logMAR 0.6±0.4)改善至最终20/40(0.3±0.5)(P=0.005),未报告显著副作用。

要点

  • 11例(21眼)难治性非感染性后葡萄膜炎患者接受静脉利妥昔单抗治疗,平均随访29.3±7.8个月。
  • 末次随访时9例(81.8%)患者荧光素眼底血管造影炎症体征得到控制。
  • 最佳矫正视力从基线20/80(logMAR 0.6±0.4)改善至最终20/40(0.3±0.5)(P=0.005)。

核心结论

  • 利妥昔单抗治疗与对其它治疗不耐受或无应答的难治性非感染性后葡萄膜炎患者的病情稳定和缓解相关。

研究设计与样本

  • 回顾性病例系列,纳入2010至2015年间接受静脉利妥昔单抗输注治疗、诊断为难治性非感染性后葡萄膜炎的患者,随访至少24个月。

主要发现

  • 共纳入11例(21眼)难治性后葡萄膜炎患者,其中女性9例(81.8%),平均随访29.3±7.8个月。
  • 7例(63.7%)患者因既往其他治疗无效而将利妥昔单抗作为补充治疗,4例(36.3%)不能耐受其他药物的患者仅接受利妥昔单抗治疗。
  • 末次随访时9例(81.8%)患者荧光素眼底血管造影炎症体征得到控制。
  • 基线最佳矫正视力为20/80(最小分辨角对数0.6±0.4),最终最佳矫正视力为20/40(0.3±0.5)(P=0.005)。
  • 未报告显著副作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess long-term effectiveness of rituximab therapy for refractory noninfectious uveitis affecting the posterior segment. METHODS: Retrospective case series. Patients diagnosed with recalcitrant noninfectious posterior uveitis who were treated with rituximab intravenous infusions between 2010 and 2015 were included. Patients underwent best-corrected visual acuity testing and fluorescein angiography evidence of disk or vascular staining at 6, 12, 18, and 24 months. Patients had at least 24 months of follow-up. RESULTS: Eleven patients (21 eyes) with refractory posterior uveitis treated with intravenous rituximab were included. Nine (81.8%) patients were female. Mean follow-up was 29.3 ± 7.8 months. rituximab was administered as complementary therapy because of previous inefficacy of other therapies in 7 (63.7%) patients, and it was the only treatment in four (36.3%) patients who did not tolerate other drugs. Inflammation signs by fluorescein angiography were controlled in nine (81.8%) patients at the end of follow-up. Baseline best-corrected visual acuity was 20/80 (logarithm of the minimal angle of resolution 0.6 ± 0.4), and final best-corrected visual acuity was 20/40 (0.3 ± 0.5) (P = 0.005). No significant side effects were reported. CONCLUSION: Rituximab therapy was associated with stability and remission of recalcitrant noninfectious posterior uveitis in patients who did not tolerate or did not respond to other therapies.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Lasave AF, You C, Ma L, et al. LONG-TERM OUTCOMES OF RITUXIMAB THERAPY IN PATIENTS WITH NONINFECTIOUS POSTERIOR UVEITIS REFRACTORY TO CONVENTIONAL IMMUNOSUPPRESSIVE THERAPY. Retina. 2018. PMID: 28225369. doi:10.1097/IAE.0000000000001563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。